Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144


PPARδ as a Metabolic Initiator of Mammary Neoplasia and Immune Tolerance.

Glazer RI.

PPAR Res. 2016;2016:3082340. doi: 10.1155/2016/3082340. Epub 2016 Dec 18. Review.


In Vitro Cytotoxic Effects of Celecoxib, Mefenamic Acid, Aspirin and Indometacin on Several Cells Lines.

Hashemipour MA, Mehrabizadeh Honarmand H, Falsafi F, Tahmasebi Arashlo M, Rajabalian S, Gandjalikhan Nassab SA.

J Dent (Shiraz). 2016 Sep;17(3):219-25.


Impact of cyclooxygenase-2 over-expression on the prognosis of breast cancer patients.

Güler SA, Uğurlu MÜ, Kaya H, Şen S, Nazlı Y, Güllüoğlu BM.

Ulus Cerrahi Derg. 2015 Jun 1;32(2):81-8. doi: 10.5152/UCD.2016.3146. eCollection 2016.


COX-2 modulates mammary tumor progression in response to collagen density.

Esbona K, Inman D, Saha S, Jeffery J, Schedin P, Wilke L, Keely P.

Breast Cancer Res. 2016 Mar 22;18(1):35. doi: 10.1186/s13058-016-0695-3.


Biomarkers in triple negative breast cancer: A review.

Yadav BS, Chanana P, Jhamb S.

World J Clin Oncol. 2015 Dec 10;6(6):252-63. doi: 10.5306/wjco.v6.i6.252. Review.


Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer.

Kim S, Shore DL, Wilson LE, Sanniez EI, Kim JH, Taylor JA, Sandler DP.

BMC Cancer. 2015 Dec 16;15:960. doi: 10.1186/s12885-015-1979-1.


Deletion of cyclooxygenase-2 inhibits K-ras-induced lung carcinogenesis.

Pan Y, Jiang Y, Tan L, Ravoori MK, Gagea M, Kundra V, Fischer SM, Yang P.

Oncotarget. 2015 Nov 17;6(36):38816-26. doi: 10.18632/oncotarget.5558.


Targeting the COX-2 Pathway to Improve Therapeutic Response in the Obese Breast Cancer Patient Population.

Bowers LW, deGraffenried LA.

Curr Pharmacol Rep. 2015 Oct 1;1(5):336-345. Epub 2015 Apr 22.


Aberrant activation of NF-κB signaling in mammary epithelium leads to abnormal growth and ductal carcinoma in situ.

Barham W, Chen L, Tikhomirov O, Onishko H, Gleaves L, Stricker TP, Blackwell TS, Yull FE.

BMC Cancer. 2015 Sep 30;15:647. doi: 10.1186/s12885-015-1652-8.


Obesity and cancer: mechanistic insights from transdisciplinary studies.

Allott EH, Hursting SD.

Endocr Relat Cancer. 2015 Dec;22(6):R365-86. doi: 10.1530/ERC-15-0400. Epub 2015 Sep 15. Review.


Association between 8473T>C polymorphism in the cyclooxygenase-2 gene and the risk of nasopharyngeal carcinoma.

Wang JL, Wang X, Yang D, Shi WJ.

Int J Clin Exp Pathol. 2015 Apr 1;8(6):7441-5. eCollection 2015.


Ethanol enhances arsenic-induced cyclooxygenase-2 expression via both NFAT and NF-κB signalings in colorectal cancer cells.

Wang L, Hitron JA, Wise JT, Son YO, Roy RV, Kim D, Dai J, Pratheeshkumar P, Zhang Z, Xu M, Luo J, Shi X.

Toxicol Appl Pharmacol. 2015 Oct 15;288(2):232-9. doi: 10.1016/j.taap.2015.07.019. Epub 2015 Jul 26.


Celecoxib attenuates retinal angiogenesis in a mouse model of oxygen-induced retinopathy.

Liu N, Chen L, Cai N.

Int J Clin Exp Pathol. 2015 May 1;8(5):4990-8. eCollection 2015.


Marketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists' arsenal.

Papanagnou P, Baltopoulos P, Tsironi M.

Ther Clin Risk Manag. 2015 May 18;11:807-19. doi: 10.2147/TCRM.S82049. eCollection 2015. Review.


Immunohistochemical analysis of COX-2 expression in dentigerous cyst, keratocystic odontogenic tumor and ameloblastoma: A comparative study.

Seyedmajidi M, Shafaee S, Siadati S, Moghaddam EA, Ghasemi N, Bijani A, Najafi M.

Dent Res J (Isfahan). 2015 May-Jun;12(3):278-84.


Epigenetic silencing of microRNA-149 in cancer-associated fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor microenvironment.

Li P, Shan JX, Chen XH, Zhang D, Su LP, Huang XY, Yu BQ, Zhi QM, Li CL, Wang YQ, Tomei S, Cai Q, Ji J, Li JF, Chouchane L, Yu YY, Sun FZ, Xu ZH, Liu BY, Zhu ZG.

Cell Res. 2015 May;25(5):588-603. doi: 10.1038/cr.2015.51. Epub 2015 Apr 28.


Herpesviral G protein-coupled receptors activate NFAT to induce tumor formation via inhibiting the SERCA calcium ATPase.

Zhang J, He S, Wang Y, Brulois K, Lan K, Jung JU, Feng P.

PLoS Pathog. 2015 Mar 26;11(3):e1004768. doi: 10.1371/journal.ppat.1004768. eCollection 2015 Mar.


Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients.

Sicking I, Rommens K, Battista MJ, Böhm D, Gebhard S, Lebrecht A, Cotarelo C, Hoffmann G, Hengstler JG, Schmidt M.

BMC Cancer. 2014 Dec 15;14:952. doi: 10.1186/1471-2407-14-952.


Animal models and therapeutic molecular targets of cancer: utility and limitations.

Cekanova M, Rathore K.

Drug Des Devel Ther. 2014 Oct 14;8:1911-21. doi: 10.2147/DDDT.S49584. eCollection 2014. Review.


Cyclooxygenase-2 and the inflammogenesis of breast cancer.

Harris RE, Casto BC, Harris ZM.

World J Clin Oncol. 2014 Oct 10;5(4):677-92. doi: 10.5306/wjco.v5.i4.677. Review.

Supplemental Content

Support Center